Key facts
- Notable investors include Tailong VC, Hangzhou Hi-Tech Financial Investment Group, Shanghai Zhonghuijin Investment Group, Panlin Capital, Qiji Investment — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for DNano MetaBio
- ·The full record, as it builds
Funding rounds
No funding rounds for DNano MetaBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DNano MetaBio
Developer of nucleic acid nanocarriers designed to realize the precise, efficient and safe delivery of drugs in the human body. The company is committed to constructing targeting carriers based on self-assembled nucleic acid structures, to achieve precise delivery of small nucleic acid drugs at the organ and cell levels, providing medical industry users with innovative medical support.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2022
- Employees
- 13
- Website
- dnanotech.bio/
- Ownership
- Privately Held (backing)
DNano MetaBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DNano MetaBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DNano MetaBio in its N-PORT filings yet. We sweep new filings monthly.